Loading clinical trials...
Loading clinical trials...
CaRi-Heart® Assessment of Risk and Evaluation of Inflammation in Coronary CT Angiography (CARE-CCTA): A Prospective U.S. Community-Based Study on the Impact of CaRi-Heart® Analysis in Patients Undergoing CCTA for Coronary Artery Disease
This study evaluates the use of CaRi-Heart® analysis, an artificial-intelligence (AI) software tool that measures inflammation in the coronary arteries using images already captured during a standard Coronary CT Angiography (CCTA) exam. The goal is to determine whether the additional information provided by CaRi-Heart® changes clinical decision-making and helps improve early identification and management of coronary artery disease in community imaging centers. Patients who undergo CCTA as part of their regular care will be invited to have their scans analyzed using CaRi-Heart® at no extra cost, time, or radiation.
This is a prospective, community-based interventional study designed to assess the incremental value of CaRi-Heart® analysis in patients undergoing Coronary CT Angiography (CCTA) for evaluation of suspected or known coronary artery disease. CaRi-Heart® is a software-as-a-medical-device (SaMD) that uses advanced AI algorithms to quantify coronary inflammation and generate a CaRi-Heart® Risk Score from existing CCTA images. The analysis provides color-coded visualization and quantitative metrics that may improve risk stratification beyond traditional plaque and stenosis assessment. The study aims to compare management decisions made before and after review of the CaRi-Heart® analysis, measuring how often the additional information influences diagnostic interpretation or changes treatment recommendations (such as preventive therapy or referral). Approximately 15,000 participants will be enrolled across multiple outpatient imaging centers in Michigan. All data will be collected under standard clinical workflows with IRB approval, informed consent, and HIPAA compliance. No additional scanning, contrast, or radiation exposure will occur.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Corazon Imaging
Bay City, Michigan, United States
Corazon Imaging
Berkley, Michigan, United States
Corazon Imaging
Caro, Michigan, United States
Corazon Imaging
Dearborn, Michigan, United States
Corazon Imaging
Flint, Michigan, United States
Corazon Imaging
Grand Rapids, Michigan, United States
Corazon Imaging
Livonia, Michigan, United States
Corazon Imaging
Macomb, Michigan, United States
Corazon Imaging
Madison Heights, Michigan, United States
Corazon Imaging
Mount Pleasant, Michigan, United States
Start Date
December 1, 2025
Primary Completion Date
January 1, 2028
Completion Date
July 1, 2028
Last Updated
October 23, 2025
15,000
ESTIMATED participants
CaRi-Heart® Analysis
DEVICE
Lead Sponsor
Corazon Medical PC
NCT01143454
NCT07241390
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions